Westchester gov.com

George Latimer
County Executive

WHEREAS, a vacancy exists in the membership of the Westchester County Laboratories and Research Board of Managers:

NOW, THEREFORE, I, George Latimer, County Executive of Westchester County, in accordance with the terms and provisions of the Westchester County Charter, appoint Dr. Lori Morton, 586 King Street, Chappaqua, New York as a member of the Westchester County Laboratories and Research Board of Managers, for the term January 1, 2021 to December 31, 2025.

Given under my hand
and seal this 1st day
of January, 2021.

George Latimer
County Executive

Office of the County Executive

Michaelian Office Building
148 Martine Avenue
White Plains, New York 10601

Email: CE@westchestergov.com
Telephone: (914)995-2900

westchestergov.com

Westchester gov.com

George Latimer
County Executive

December 31, 2020

Dr. Lori Morton
586 King Street
Chappaqua, NY 10514

Dear Dr. Morton,

It is my pleasure to appoint you to serve as a member of the Westchester County Laboratories and Research Board of Managers, pursuant to the Laws of Westchester County §261.91. This appointment is for a term to commence on January 1, 2021 and expire on December 31, 2025.

Your appointment is subject to confirmation by the Westchester County Board of Legislators, but your service begins immediately. You must complete the attached Oath of Office and file it with the County Clerk prior to the next Laboratories and Research Board of Managers meeting, and provide this office with a copy within 30 days. Please contact the Westchester County Department of Laboratories and Research at (914) 231-1715 for the date, place, and time of the upcoming Laboratories and Research Board of Managers meeting for your participation.

When you have filed your Oath of Office, a Resolution to confirm your appointment will be submitted to the County Board of Legislators. As part of the confirmation process, you may be called before the Board to be interviewed.

Pursuant to Local Law, as a member of a Westchester County Board and/or Commission, you are responsible for adhering to the requirements of our Code of Ethics, which includes the annual filing of a financial disclosure statement with the County Board of Ethics. A financial disclosure form is attached.

Warmest wishes for a successful tenure.

Very Truly Yours,

George Latimer
Westchester County Executive

GL/wm

cc: Honorable Board of Legislators
Dr. Aleksandar Milovanovic, Acting Westchester County Pathologist/Medical Examiner
Joan McDonald, Director of Operations

Office of the County Executive

Michaelian Office Building
148 Martine Avenue
White Plains, New York 10601

Email: ce@westchestergov.com
Telephone: (914)995-2900

westchestergov.com

Lori Gowen Morton, Ph.D.

Director, Cardiovascular and Fibrosis Research
Regeneron Pharmaceuticals
Work e-mail: lori.morton@regeneron.com
Personal email: lcgmorton@gmail.com

Biographical Sketch

Dr. Lori Morton is the Vice President of Cardiovascular Research and the Fibrosis Research at Regeneron Pharmaceuticals. In that role, Dr. Morton leads a team of scientists in the discovery and validation of new targets for the treatment of a wide variety of diseases affecting heart, kidney, lung and vascular function, as well as a number of diseases characterized by tissue scarring (fibrosis). Once interesting approaches to treat disease are identified, Dr. Morton's group collaborates with a number of other research groups at Regeneron to develop and test new drugs, determining the best drug candidates for new clinical programs and providing scientific leadership throughout clinical development.

Dr. Morton has a Bachelor or Arts degree in Biological Sciences from Douglass College of Rutgers University and a Ph.D. in Genetics and Molecular Biology from the University of North Carolina at Chapel Hill. Dr. Morton's graduate research involved the use of genetic modification in mice to explore the biology of the breast cancer gene, BRCA1. Following her Ph.D., Dr. Morton was a post-doctoral fellow at Pfizer Pharmaceuticals, characterizing genetically modified mice deficient in the OF45 gene, a protein involved in determination of bone density. As a Pfizer fellow, Dr. Morton then transferred to Memorial Sloan Kettering Cancer Center, where she studied co-activators of nuclear receptor (Vitamin D, TSH, Estrogen, etc.) transcription. In 2002, Dr. Morton joined Regeneron Pharmaceuticals in the Neuroendocrinology and Obesity Research group, and initiated cardiovascular studies to better understand the function of a number of genes and proteins on blood pressure, cardiac and renal function. These efforts have grown into the present Cardiovascular Research group.

Research Interests

Currently oversee a 30-member team of scientists engaged in target discovery, target validation and biologics drug development in the areas of acute and chronic kidney disease, cardiac injury and failure, complement dysregulation, systemic and pulmonary hypertension, coagulation, pulmonary, liver, renal, cardiac, and skin fibrosis.

Education

Ph.D., Genetics and Molecular Biology 1999

University of North Carolina at Chapel Hill, Chapel Hill, NC.

Dissertation title: The role of the tumor suppressor *Brca1* in murine development, cell growth and tumorigenesis. Thesis advisor: Beverly H. Koller, Ph.D.

B.A., Biology 1993

Douglass College of Rutgers University, New Brunswick, NJ

Experience

- Vice President, Cardiovascular and Renal Research, Fibrosis Research, **Regeneron Pharmaceuticals**, Tarrytown, NY — 2019-present
- Senior Director, Cardiovascular and Renal Research, Fibrosis Research, **Regeneron Pharmaceuticals**, Tarrytown, NY — 2018-2019
- Director, Cardiovascular and Renal Research, Fibrosis Research, **Regeneron Pharmaceuticals**, Tarrytown, NY — 2015-2017
- Associate Director, Cardiovascular and Renal Research, Fibrosis Research, **Regeneron Pharmaceuticals**, Tarrytown, NY — 2012-2015
- Senior Staff Scientist, Cardiovascular and Renal Research, **Regeneron Pharmaceuticals**, Tarrytown, NY — 2008-2011
- Staff Scientist, Cardiovascular and Renal Research, **Regeneron Pharmaceuticals**, Tarrytown, NY — 2006-2007
- Staff Scientist, Neuroendocrinology and Obesity, **Regeneron Pharmaceuticals**, Tarrytown, NY — 2005-2006
- Scientist, Neuroendocrinology and Obesity, **Regeneron Pharmaceuticals**, Tarrytown, NY — 2002-2005
- Research Fellow, Department of Cell Biology, Sloan-Kettering Institute, **Memorial Sloan Kettering Cancer Center**, New York, NY. *Laboratory of Leonard P. Freedman, Ph.D.* — 2000-2002
- Research Fellow, Department of Cardiovascular and Metabolic Diseases, **Pfizer, Inc.** Groton, CT. *Laboratory of Thomas A. Brown, Ph.D.* — 1999-2000

Publications

Devalaraja-Narashimha K, Meagher K, Luo Y, Huang C, Kaplan T, Muthuswamy A, Halasz G, Casanova S, O'Brien J, Peyser Boiarsky R, McWhirter J, Gartner H, Bai Y, MacDonnell S, Liu C, Hu Y, Latuszek A, Wei Y, Prasad S, Huang T, Yancopoulos G, Murphy A, Olson W, Zambrowicz B, Macdonald L, Morton LG. "Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy." **J Am Soc Nephrol.** 2020 Online ahead of print.

Latuszek A, Liu Y, Olsen O, Foster R, Cao M, Lovric I, Yuan M, Liu N, Chen H, Zhang Q, Xiao H, Springer C, Ehrlich G, Kamat V, Rafique A, Hu Y, Krueger P, Huang T, Poueymirou W, Babb R, Rosconi MP, Retter MW, Chen G, Morton L, Zambrowicz B, Cao J, Romano C, Olson WC. "Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5." **PLoS One.** 2020 May 8;15(5):e0231892.

Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study. Townsend RR, Guarnieri P, Argyropoulos C, Blady S, Boustany-Kari CM, Devalaraja-Narashimha K, Morton L, Mottl AK, Patel U, Palmer M, Ross MJ, Sarov-Blat L, Steinbugler K, Susztak K; TRIDENT Study Investigators. **Kidney Int.** 2020 Jan;97(1):10-13. doi: 10.1016/j.kint.2019.09.020.

Macdonald LE, Meagher KA, Franklin MC, Levenkova N, Hansen J, Badithe AT, Zhong M, Krueger P, Rafique A, Tu N, Shevchuk J, Wadhwa S, Ehrlich G, Bautista J, Grant C, Esau L, Poueymirou WT, Auerbach W, Morton L, Babb R, Chen G, Huang T, MacDonald D, Graham K, Gurer C, Voronina VA, McWhirter JR, Guo C, Yancopoulos GD, Murphy AJ. Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties. **Proc Natl Acad Sci U S A.** 2020 Jan 7;117(1):292-299.

Peyser R, MacDonnell S, Gao Y, Cheng L, Kim Y, Kaplan T, Ruan Q, Wei Y, Ni M, Adler C, Zhang W, Devalaraja-Narashimha K, Grindley J, Halasz G, Morton L. Defining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell Sequencing. **Am J Respir Cell Mol Biol.** 2019 Jul;61(1):74-85.

Gross O, Kashtan CE, Rheault MN, Flinter F, Savige J, Miner JH, Torra R, Ars E, Deltas C, Savva I, Perin L, Renieri A, Ariani F, Mari F, Baigent C, Judge P, Knebelman B, Heidet L, Lagas S, Blatt D, Ding J, Zhang Y, Gale DP, Prunotto M, Xue Y, Schachter AD, Morton LCG, Blem J, Huang M, Liu S, Vallee S, Renault D, Schifter J, Skelding J, Gear S, Friede T, Turner AN, Lennon R. Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome.
Nephrol Dial Transplant. 2017 Jun 1;32(6):916-924.

Wei K, Piecewicz SM, McGinnis LM, Taniguchi CM, Wiegand SJ, Anderson K, Chan CW, Mulligan KX, Kuo D, Yuan J, Vallon M, Morton LC, Lefai E, Simon MC, Maher JJ, Mithieux G, Rajas F, Annes JP, McGuinness OP, Thurston G, Giaccia AJ, Kuo CJ. A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. **Nat Med.** 2013 Oct;19(10):1331-7.

Raz R, Stricker S, Gazzerro E, Clor JL, Witte F, Nistala H, Zabski S, Pereira RC, Stadmeyer L, Wang X, Gowen L, Sleeman MW, Yancopoulos GD, Canalis E, Mundlos S, Valenzuela DM, Economides AN. The mutation ROR2W749X, linked to human BDB, is a recessive mutation in the mouse, causing

brachydactyly, mediating patterning of joints and modeling recessive Robinow syndrome. Development. 2008 May;135(9):1713-23.

Torres R, Croll SD, Vercollone J, Reinhardt J, Griffiths J, Zabski S, Anderson KD, Adams NC, Gowen L, Sleeman MW, Valenzuela DM, Wiegand SJ, Yancopoulos GD, Murphy AJ. Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responses. Pain. 2007 Aug;130(3):267-78.

Xu J, Gowen L, Raphalides C, Hoyer KK, Weinger JG, Renard M, Troke JJ, Vaitheesyaran B, Lee WN, Saad MF, Sleeman MW, Teitell MA, Kurland IJ. Decreased hepatic futile cycling compensates for increased glucose disposal in the Pten heterodeficient mouse. Diabetes. 2006 Dec;55(12):3372-80.

Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76

Macdonald LE, Wortley KE, Gowen LC, Anderson KD, Murray JD, Poueymirou WT, Simmons MV, Barber D, Valenzuela DM, Economides AN, Wiegand SJ, Yancopoulos GD, Sleeman MW, Murphy AJ. Resistance to diet-induced obesity in mice globally overexpressing OGH/GPB5. Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2496-501.

Sleeman MW, Wortley KE, Lai KM, Gowen LC, Kintner J, Kline WO, Garcia K, Stitt TN, Yancopoulos GD, Wiegand SJ, Glass DJ. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med. 2005 Feb;11(2):199-205.

Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem. 2003 Jan 17;278(3):1998-2007.

Bennett LM, McAllister KA, Malphurs J, Ward T, Collins NK, Seely JC, Gowen LC, Koller BH, Davis BJ, Wiseman RW. Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Cancer Res. 2000 Jul 1;60(13):3461-9.

Snouwaert JN, Gowen LC, Latour AM, Mohn AR, Xiao A, DiBiase L, Koller BH. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene.

Oncogene. 1999 Dec 20;18(55):7900-7.

Cressman VL, Backlund DC, Hicks EM, Gowen LC, Godfrey V, Koller BH. Mammary tumor formation in p53- and BRCA1-deficient mice. Cell Growth Differ. 1999 Jan;10(1):1-10.

Hanford MG, Rushton BC, Gowen LC, Farber RA. Microsatellite mutation rates in cancer cell lines deficient or proficient in mismatch repair. Oncogene. 1998 May 7;16(18):2389-93.

Snouwaert JN, Gowen LC, Lee V, Koller BH. Characterization of Brca1 deficient mice. Breast Dis. 1998 Apr;10(1-2):33-44.

Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet. 1996 Feb;12(2):191-4.

Krishnamoorthy A, Gowen LC, Boll KE, Knuppel RA, Sciorra LJ. Chromosome and interphase analysis of placental mosaicism in intrauterine growth retardation. J Perinatol. 1995 Jan-Feb;15(1):47-50.

Patents

Available upon request

Affiliations/Memberships

- American Heart Association 2003-present
- New York Academy of Science 2008-present

Corporate Service

- Regeneron R&Pd Diversity, Equity and Inclusion Committee 2020-present
- Regeneron Post-Doctoral Steering Committee 2016-present
- Regeneron STEM Education Committee 2012-present
- Regeneron Institutional Animal Care and Use Committee 2003-2013

Community involvement

- **New Castle Town Board**, Committee member 2021
- **New Castle Democratic Committee**, District Leader January 2017-present
- **Up2Us**, Board of Directors, Founding member April 2015-present

- **Chappaqua PTA STEM Committee**, Chair (Sep 2016-June 2019), Founding Member — 2014-present
- **New Castle Master Plan, Housing Committee** — 2014
- **Chappaqua Children's Book Festival**, Board of Directors — 2012-present
- **Westchester Heart Walk**, American Heart Association — 2016-present
    - Executive Leadership Committee, 2016 Executive Director, 2017

- **Regeneron Science Outreach** — 2002-present
    - Regeneron Kids Day coordinator, School Guest Speaker, Hands on Science demonstrations, Advocate for STEM programming and resources.

Awards

- **Regeneron Volunteer of the Year**, honorable mention — 2017
- **Regeneron Volunteer of the Year** — 2018
- **Point of Light foundation**, Daily Point of Light # 6446 — 2019
    - https://www.pointsoflight.org/awards/scientist-sparks-discovery-and-spreads-awareness-of-stem-through-volunteerism/
- **914 Inc. Women in Business Award** — 2019
    - http://www.westchestermagazine.com/914-INC/Q4-2019/Women-in-Business-2019/Lori-Morton-PhD/

COUNTY OF WESTCHESTER
OATH OF OFFICE
For Appointees to County Boards and Commissions

STATE OF NEW YORK)
) ss.:
COUNTY OF WESTCHESTER)

I, LORI Morton (Print or Type Name) do solemnly swear (or affirm) that I will support the constitution of the United States, and the constitution of the State of New York, and that I will faithfully discharge the duties of the office of Board Member, Laboratories and Research Board of Managers in and for the County of Westchester, according to the best of my ability.

Date: January 13, 2021

(Signature)

Sworn to and subscribed before me this 13 day of January, 2021.

(Signature)

Christina Papes

(Print or Type Name)

Town Clerk / Notary

(Title of Official Administering Oath)

CHRISTINA M. PAPES
NOTARY PUBLIC-STATE OF NEW YORK
No. 01PA6332326
Qualified in Westchester County
My Commission Expires October 26, 2023

Mail **original** Oath of Office to Office to Andrew Ferris, Office of the County Executive, 148 Martine Ave., Room 916D, White Plains, NY 10601 for filing **within thirty (30) days** of the commencement of the term of office or the notice of appointment.